Your Metabolic Blood Test Results, Explained

A plain-language guide to reading the labs that actually describe your metabolic health.

Metabolic blood test results explained in plain terms come down to a handful of numbers that describe how your body handles sugar, fat, and waste. The panel usually reports fasting glucose and A1c, an LDL, HDL, and triglyceride lipid profile, liver enzymes, and kidney markers such as eGFR. Read together, these tell a story about metabolic health that the scale alone cannot.

What do fasting glucose and A1c actually tell me?

Fasting glucose is a snapshot. It measures the amount of sugar in your blood after you have not eaten for several hours, which is why the lab asks you to fast beforehand. A1c is the wider view. It reflects your average blood sugar over roughly the past three months, because it measures how much sugar has attached to your red blood cells over their lifespan.

I like patients to understand why we look at both. A single fasting glucose can be nudged by a stressful morning or a poor night of sleep. A1c smooths that out. When one is borderline and the other is clearly elevated, that contrast is often more useful than either number on its own. In practice, a rising A1c is one of the earliest paper signals that the body is starting to struggle with insulin, sometimes years before anyone feels a symptom.

How do I read a lipid panel: LDL, HDL, and triglycerides?

The lipid panel gets shorthanded as "cholesterol," but it is really three separate conversations. LDL is the fraction most associated with plaque building up in arteries, which is why it is often called the number to keep lower. HDL tends to run in the opposite direction; higher is generally regarded as protective. Triglycerides measure fat circulating in the blood and are closely tied to diet, alcohol, and how your body is handling insulin.

Here is something I find people rarely hear. The ratio and the pattern often matter more than any single line. A person can have a middling LDL but high triglycerides and a low HDL, and that combination frequently travels with excess visceral fat and insulin resistance. Looking at the three together, rather than fixating on one, is how a clinician reads the metabolic weather.

What do liver enzymes hint at?

Liver enzymes, commonly reported as ALT and AST, are proteins that live inside liver cells. When those cells are stressed or inflamed, small amounts leak into the bloodstream and the numbers climb. A mildly elevated ALT in someone carrying extra weight is one of the most common findings I see, and it often points toward fat accumulating in the liver rather than any acute illness.

This matters because fatty liver, now called metabolic dysfunction-associated steatotic liver disease, is quietly common and closely linked to how the whole metabolic system is running. The research here has moved quickly. In the ESSENCE trial published in the New England Journal of Medicine in 2025, semaglutide 2.4 mg improved metabolic dysfunction-associated steatohepatitis, a more advanced form of fatty liver, and improved liver fibrosis compared with placebo at 72 weeks. On the strength of that work, the FDA approved semaglutide, sold as Wegovy (Novo Nordisk; we are not affiliated), for that condition with moderate to advanced fibrosis in August 2025. Compounded semaglutide is not FDA-approved and is not identical to the brand version, and results vary by individual.

What are kidney markers like eGFR?

Your kidneys filter waste out of the blood, and eGFR, the estimated glomerular filtration rate, is the lab's best estimate of how well that filter is working. It is calculated from a blood marker called creatinine along with your age and other factors. A higher eGFR generally means stronger filtering capacity; a declining one is worth watching over time.

Kidney health and metabolic health are deeply connected, and the field has produced striking evidence on that front. In the FLOW trial published in 2024, among adults with type 2 diabetes and chronic kidney disease, semaglutide reduced major kidney events by about 24 percent, reduced major cardiovascular events by about 18 percent, and reduced death from any cause by about 20 percent. Those results are for the FDA-approved brand product in a specific studied population, not a promise for any individual, but they explain why a metabolic physician pays attention to kidney markers rather than treating them as an afterthought.

What does metabolic health look like on paper?

When I describe a healthy metabolic panel to a patient, I am usually pointing at a pattern rather than one hero number. Fasting glucose and A1c sitting in the normal range. Triglycerides that are not running high, with an HDL that is not scraping the floor. Liver enzymes calm. An eGFR that reflects steady filtering. None of these lives in isolation; they move as a system, and when several drift in the same direction, that drift is the finding.

The reassuring part is that this system is responsive. Modest, sustained weight loss, better sleep, more muscle, and fewer refined carbohydrates can move all of these numbers in a favorable direction at once. That is the deeper reason we test. The labs turn an abstract goal into something you can watch change.

Why is the scale only one number?

The scale is honest but shallow. It cannot tell you whether the weight you carry is metabolically quiet or metabolically loud. Two people at the same weight can have very different glucose, triglyceride, and liver numbers depending on where the fat sits and how their bodies handle insulin. That is why I ask patients to hold the scale loosely and read the panel closely.

It also cuts the other way during treatment. There are stretches where the scale barely moves while the lab work quietly improves, and I count that as progress that a bathroom scale would have missed entirely. If we only measured pounds, we would be blind to most of what actually protects your heart, liver, and kidneys.

How can these numbers improve with weight loss and therapy?

Meaningful weight loss tends to pull the whole panel in a better direction, and modern therapy has raised what is achievable. In the STEP-1 trial, participants lost about 14.9 percent of body weight on average with semaglutide; in SURMOUNT-1, the average was about 20.9 percent with tirzepatide. There is also cardiovascular evidence behind these effects: the SELECT trial found that semaglutide, sold as Wegovy (Novo Nordisk; we are not affiliated), reduced major cardiovascular events by about 20 percent in adults with established cardiovascular disease and overweight or obesity who did not have diabetes.

A few honest caveats belong here. Compounded semaglutide and tirzepatide are not FDA-approved and are not identical to the brand versions, and individual results vary. Obesity behaves like a long-term condition; in the STEP-1 extension, roughly two-thirds of the lost weight returned within a year after stopping, which is why we plan for the long run rather than a sprint. And because rapid weight loss can pull lean tissue along with fat, sometimes accounting for a quarter to 40 percent of what is lost, I pair therapy with strength training and adequate protein, often around 1.2 to 2 grams per kilogram of body weight per day, to protect muscle while the labs improve.

How we use your labs at New Hope Weight Loss

At New Hope Weight Loss and Wellness, our telehealth visits are built around reading these numbers with you rather than at you. A visit with Dr. Anjmun Sharma, MD is $119. For those who want a structured start, the 90-day Reset is $499 with compounded semaglutide (about $166 a month, roughly $5.50 a day) or $699 with compounded tirzepatide (about $233 a month, roughly $7.70 a day), and a one-month $199 Skeptics Trial exists for people who simply want to see how their own body responds. Everything is cash-pay, HIPAA-private, and bilingual, with no insurance required. Your numbers are yours; our job is to help you read them and, when it makes sense, to help them improve.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.